JP2011517683A - 疎水性タキサン誘導体の組成物およびその使用 - Google Patents

疎水性タキサン誘導体の組成物およびその使用 Download PDF

Info

Publication number
JP2011517683A
JP2011517683A JP2011503961A JP2011503961A JP2011517683A JP 2011517683 A JP2011517683 A JP 2011517683A JP 2011503961 A JP2011503961 A JP 2011503961A JP 2011503961 A JP2011503961 A JP 2011503961A JP 2011517683 A JP2011517683 A JP 2011517683A
Authority
JP
Japan
Prior art keywords
composition
composition according
unsubstituted
alkyl
taxane derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011503961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517683A5 (OSRAM
Inventor
ニール ピー． デサイ，
チャンリン タオ，
タパス デ，
シェリー シャオペイ チー，
ヴォン トリュー，
Original Assignee
アブラクシス バイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス， エルエルシー filed Critical アブラクシス バイオサイエンス， エルエルシー
Publication of JP2011517683A publication Critical patent/JP2011517683A/ja
Publication of JP2011517683A5 publication Critical patent/JP2011517683A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011503961A 2008-04-10 2008-09-12 疎水性タキサン誘導体の組成物およびその使用 Pending JP2011517683A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4400608P 2008-04-10 2008-04-10
US61/044,006 2008-04-10
PCT/US2008/076179 WO2009126175A1 (en) 2008-04-10 2008-09-12 Compositions of hydrophobic taxane derivatives and uses thereof

Publications (2)

Publication Number Publication Date
JP2011517683A true JP2011517683A (ja) 2011-06-16
JP2011517683A5 JP2011517683A5 (OSRAM) 2012-10-18

Family

ID=40456809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011503961A Pending JP2011517683A (ja) 2008-04-10 2008-09-12 疎水性タキサン誘導体の組成物およびその使用

Country Status (5)

Country Link
JP (1) JP2011517683A (OSRAM)
KR (2) KR20150136137A (OSRAM)
RU (1) RU2010145529A (OSRAM)
TW (1) TW200942233A (OSRAM)
WO (1) WO2009126175A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
ES2764100T3 (es) 2009-04-15 2020-06-02 Abraxis Bioscience Llc Composiciones de nanopartículas exentas de priones y métodos
US9211283B2 (en) * 2009-12-11 2015-12-15 Biolitec Pharma Marketing Ltd Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
EP2552438B1 (en) 2010-03-26 2016-05-11 Abraxis BioScience, LLC Methods of treatment of hepatocellular carcinoma
CA2794147A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
BR112012024442A2 (pt) 2010-03-29 2017-03-21 Abraxis Bioscience Llc métodos de tratamento de câncer
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
EP3056201A1 (en) 2010-06-07 2016-08-17 Abraxis BioScience, LLC Combination therapy methods for treating proliferative diseases
EP2447268A1 (en) 2010-10-29 2012-05-02 INDENA S.p.A. Crystalline form of 13-[(N-tert-butoxycarbonyl)-2'-O-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin III
EP2773322A1 (en) 2011-11-01 2014-09-10 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
HUE045661T2 (hu) 2011-12-14 2020-01-28 Abraxis Bioscience Llc Polimer segédanyagok alkalmazása részecskék liofilizálásához vagy fagyasztásához
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968191B1 (en) 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
LT3313401T (lt) 2015-06-29 2022-01-10 Abraxis Bioscience, Llc Nanodalelės, apimančios sirolimą ir albuminą, skirtos naudoti epitelioidinių ląstelių navikų gydymui
AU2016323770A1 (en) * 2015-09-16 2018-03-29 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
US11730736B2 (en) 2017-11-06 2023-08-22 Rapt Therapeutics, Inc. Anticancer agents
BR112020018910A2 (pt) 2018-03-20 2020-12-29 Abraxis Bioscience, Llc Métodos de tratamento de transtorno do sistema nervoso central através da administração de nanopartículas de um unibidor de mtor e de uma albumina
JP2022553426A (ja) 2019-10-28 2022-12-22 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507075A (ja) * 1993-02-22 1996-07-30 ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
JP2001501931A (ja) * 1996-10-01 2001-02-13 ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド 蛋白質安定化した薬理学的活性薬剤、その製造方法およびその使用方法
JP2001519755A (ja) * 1995-09-12 2001-10-23 ザ リポソーム カンパニー、インコーポレーテッド 加水分解促進性のタキサン疎水性誘導体
JP2002507976A (ja) * 1997-06-27 2002-03-12 ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド 薬理薬物の新規製剤、その製造法及びその使用法
JP2003521514A (ja) * 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 抗腫瘍剤としてのｃ１０ヘテロ置換アセテートタキサン
WO2006089207A2 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO2006091780A2 (en) * 2005-02-24 2006-08-31 Elan Pharma International Limited Nanoparticulate formulations of docetaxel and analogues thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507075A (ja) * 1993-02-22 1996-07-30 ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
JP2001519755A (ja) * 1995-09-12 2001-10-23 ザ リポソーム カンパニー、インコーポレーテッド 加水分解促進性のタキサン疎水性誘導体
JP2001501931A (ja) * 1996-10-01 2001-02-13 ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド 蛋白質安定化した薬理学的活性薬剤、その製造方法およびその使用方法
JP2002507976A (ja) * 1997-06-27 2002-03-12 ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド 薬理薬物の新規製剤、その製造法及びその使用法
JP2003521514A (ja) * 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 抗腫瘍剤としてのｃ１０ヘテロ置換アセテートタキサン
WO2006089207A2 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5011000915; ＡＬＩ　Ｓ: 'ＨＹＤＲＯＬＹＺＡＢＬＥ　ＨＹＤＲＯＰＨＯＢＩＣ　ＴＡＸＡＮＥＳ：　ＳＹＮＴＨＥＳＩＳ　ＡＮＤ　ＡＮＴＩ-ＣＡＮＣＥＲ　ＡＣＴＩＶＩＴＩＥＳ' ＡＮＴＩ-ＣＡＮＣＥＲ　ＤＲＵＧＳ Ｖ１２　Ｎ２, 20010201, Ｐ１１７-１２８, ＲＡＰＩＤ　ＣＯＭＭＵＮＩＣＡＴＩＯＮＳ *

Also Published As

Publication number Publication date
RU2010145529A (ru) 2012-05-20
TW200942233A (en) 2009-10-16
WO2009126175A1 (en) 2009-10-15
KR20100133475A (ko) 2010-12-21
KR20150136137A (ko) 2015-12-04

Similar Documents

Publication Publication Date Title
JP2011517683A (ja) 疎水性タキサン誘導体の組成物およびその使用
CA2721153C (en) Compositions of hydrophobic taxane derivatives and uses thereof
ES2788298T3 (es) Formulaciones de nanopartículas y usos de las mismas
CN107405328B (zh) 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
CN101951956B (zh) 用于水溶性差的药用活性物质给药的药物递送系统
CN112604002A (zh) 二硫键桥连的多西他赛-脂肪酸前药及其自组装纳米粒
TW201302850A (zh) 新穎之嵌段共聚物、微胞調製物及將其作為有效成分之抗癌劑
WO2007028341A1 (fr) Nanomicelles servant de medicaments anticancereux a polyethylene phospholipides glycolyles contenant des vinca alcaloides
CN110638752A (zh) 注射剂
KR20210078505A (ko) 종양내 주사 제형
CN119285582B (zh) 一种高水溶性的双乌头酸分子化学修饰紫杉醇化合物、合成方法及应用
HK1154809A (en) Nanoparticle formulations and uses thereof
HK1154809B (en) Nanoparticle formulations and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130805

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131030